JASPER THERAPEUTICS, INC

Jasper Therapeutics (JSPR) is a clinical-stage biotech focusing on safer conditioning agents and stem cell engineering for hematopoietic stem cell transplants and gene therapies. Their lead compound, JSP191, aims to reduce risks in current conditioning regimens. Recent developments include promising results for Briquilimab in preventing allergic conditions and the announcement of fiscal quarter and year-end results. The company supports its research through strategic partnerships and an inducement equity incentive plan.